A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy.
The ideal cancer treatment should both destroy the primary tumour and at the same time educate the immune system to recognise the tumour as foreign so that distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the i.v. administration of photosensitisers followed by illumination of the tumour with red light producing reactive oxygen species that eventually cause vascular shutdown and tumour cell death by apoptosis and necrosis. Anti-tumour immunity is stimulated after PDT due to the acute inflammatory response, generation of tumour-specific antigens, and induction of heat-shock proteins. Green fluorescent protein (GFP) is used as an optical reporter to noninvasively image the progression of mouse tumours, and in addition, may act as a foreign (jellyfish) antigen. We asked whether GFP-expressing tumours could be used to monitor the response of tumour-bearing mice to PDT, and whether the tumour response differed when a nonimmunogenic tumour cell line was transduced with GFP. We injected RIF-1 or RIF-1 EGFP (stably transduced with a retroviral vector) cells in the leg of C3H/HeN mice and both the cells and tumour grew equally well. We used PDT with benzoporphyrin derivative and a short drug-light interval. There were complete cures and 100% mouse survival of RIF-1 EGFP while RIF-1 wild-type tumours all recurred. Cured mice were resistant to rechallenge with RIF-1 EGFP cells and a rechallenge with wild-type RIF-1 cells grew significantly slower. There was also slower RIF-1 EGFP rechallenge growth but no rejection when RIF-1 EGFP tumours were surgically removed. There was a low rate of PDT cure of tumours when RIF-1 cells were transduced with an empty retroviral vector. The presence of antibodies against EGFP in mouse serum suggests EGFP can act as a foreign antigen and PDT can then stimulate a long-term memory immune response.
Castano
A P
AP
BAR414, Wellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom Street, and Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
Liu
Q
Q
Hamblin
M R
MR
D000818:Animals; D000906:Antibodies / Q000097:blood*; D045744:Cell Line, Tumor; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000235:genetics; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000276:immunology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009364:Neoplasm Recurrence, Local / Q000276:immunology*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics; D010778:Photochemotherapy; D016896:Treatment Outcome
D000906:Antibodies; D049452:Green Fluorescent Proteins